Skip to content

THE EFFFECT OF SOMARAJI TAILAM IN THE VICHARCHIKA W S R ECZEMA

TO STUDY THE EFFICACY OF SOMARAJI TAILAM IN THE MANAGEMENT OF VICHARCHIKA W.S.R.ECZEMA(RCT)

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027795
Enrollment
100
Registered
2020-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L208- Other atopic dermatitis

Interventions

Intervention1: SOMARAJI TAILAM: SOMARAJI TAILAM for local application twice a day for 4 weeks Control Intervention1: Tacrolimus ointment 0.03%: Tacrolimus ointment 0.03% for local application twice a

Sponsors

DMM Ayurved Mahavidyalaya Yavatmal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A patient having Classical signs and symptoms of Vicharchika Kandu (Itching) Pidika (Carbuncle) Shyava (Blackish discolouration) Strava (Discharge) Ruja (Pain) Rajyo (Marked lining due to thickening of lesion) Ruksha (Dryness) Rakta (Redness in lesion)

Exclusion criteria

Exclusion criteria: Patient below 02 years and 70 years Malignancy Diabetic wound Cellulitis Patient on steroid Immuno comromise like HIV positive Secondary infection Scabies Fungal infection Hansons Disease Herpes Zoster

Design outcomes

Primary

MeasureTime frame
To study the efficacy of Somaraji tailam in the management of VicharchikaTimepoint: 0th 10th 20th 30th 40th 50th 60th day

Secondary

MeasureTime frame
1 To the study Disease Vicharchika And Eczema 2 To study the effect of Somaraji tailam in signe and symptoms of VIcharchika 3 To see the effect of Tacrolimus ointment in Vicharchika (Eczema)Timepoint: 30 days

Countries

India

Contacts

Public ContactDr Suryaprakash Jaiswal

DMM Ayurved Mahavidyalaya Yavatmal

dr.skjaiswal01@gmail.com9822126706

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026